---
title: "Olymvax Biopharmaceuticals plans to acquire a 15% stake in its controlling subsidiary, Xinnuoming Biotech"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/255332264.md"
description: "Olymvax Biopharmaceuticals plans to acquire a 15% equity stake in its controlling subsidiary, XinNuoming Biotech, with self-raised funds not exceeding 45 million yuan. The equity will come from Fund No. 1 and Jingchuang Fund. This acquisition will enhance the company's control and management efficiency over its subsidiaries, strengthening overall strategic synergy and resource integration"
datetime: "2025-08-31T07:56:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/255332264.md)
  - [en](https://longbridge.com/en/news/255332264.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/255332264.md)
---

# Olymvax Biopharmaceuticals plans to acquire a 15% stake in its controlling subsidiary, Xinnuoming Biotech

According to the announcement from Olymvax Biopharmaceuticals (688319.SH), the minority equity shareholders of its controlling subsidiary, XinNuoming Biotechnology, namely Fund No. 1 and Jingchuang Fund, plan to publicly transfer a total of 15% equity in XinNuoming Biotechnology through the Southwest United Property Rights Exchange. The company intends to acquire a total of 15% equity held by Fund No. 1 and Jingchuang Fund through a bidding process with self-raised funds not exceeding 5% above the listing base price of the target equity and not exceeding RMB 45 million. This includes the acquisition of 8.1081% equity held by Fund No. 1 and 6.8919% equity held by Jingchuang Fund.

Upon completion of this equity acquisition, it will further enhance the control and management efficiency of the subsidiary, contributing to the overall strategic synergy and resource integration of the company

### Related Stocks

- [688319.CN](https://longbridge.com/en/quote/688319.CN.md)

## Related News & Research

- [New York Governor Signs Bills To Preserve Mandatory Vaccines](https://longbridge.com/en/news/286947583.md)
- [16:51 ETPositive topline results from the pivotal Phase 3 REDUCE 2 study of pozdeutinurad in gout](https://longbridge.com/en/news/287271935.md)
- [Phase 3-ready cancer biotech Parabilis Medicines files for a $100 million IPO](https://longbridge.com/en/news/286972125.md)
- [Microbiotica reports positive results for MB097 in advanced melanoma](https://longbridge.com/en/news/286740265.md)
- [09:35 ETOpen Medicine Launches Ahead of ASCO, Introducing "Living Algorithms" for Real-Time Oncology Decision-Making](https://longbridge.com/en/news/286923155.md)